Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma.
Cho BC, Penkov K, Bondarenko I, Kurochkin A, Pikiel J, Ahn HK, Korożan ME, Osipov M, Odintsova S, Braiteh F, Ribas A, Grilley-Olson JE, Lugowska I, Bonato V, Damore MA, Yang W, Jacobs IA, Bowers M, Li M, Johnson ML. Cho BC, et al. Among authors: ahn hk. ESMO Open. 2023 Aug;8(4):101589. doi: 10.1016/j.esmoop.2023.101589. Epub 2023 Jun 27. ESMO Open. 2023. PMID: 37385154 Free PMC article. Clinical Trial.
A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11).
Kim KH, Yoon S, Ahn HK, Lee SY, Lee GW, Lee SS, Cho JH, Cho BC, Yoon HI, Lim SM. Kim KH, et al. Among authors: ahn hk. Clin Lung Cancer. 2022 Dec;23(8):e536-e539. doi: 10.1016/j.cllc.2022.07.014. Epub 2022 Aug 7. Clin Lung Cancer. 2022. PMID: 36002368
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Ochi Lohmann T, Xu T, Cardona A, Ruf T, Noe J, Solomon BJ; ALINA Investigators. Wu YL, et al. N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532. N Engl J Med. 2024. PMID: 38598794 Clinical Trial.
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17).
Kang EJ, Yang Y, Lee S, Kim YJ, Lim SM, Ahn MJ, Choi YJ, Lee Y, Kim TM, Kim I, Ahn HK, Jeung HC, Lee SI, Oh SY, Bae WK, Ryu H, Park KH, Lee KH. Kang EJ, et al. Among authors: ahn hk. ESMO Open. 2024 Sep;9(9):103668. doi: 10.1016/j.esmoop.2024.103668. Epub 2024 Aug 29. ESMO Open. 2024. PMID: 39214049 Free PMC article. Clinical Trial.
A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer.
Kim YS, Sym SJ, Park SH, Park I, Hong J, Ahn HK, Park J, Cho EK, Lee WK, Chung M, Lee JH, Shin DB. Kim YS, et al. Among authors: ahn hk. Cancer Chemother Pharmacol. 2014 Jan;73(1):163-9. doi: 10.1007/s00280-013-2334-3. Epub 2013 Nov 8. Cancer Chemother Pharmacol. 2014. PMID: 24202666 Clinical Trial.
289 results